| NCT ID | NCT03189719 |
| Title | First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme Corp. |
| Indications |
esophagus squamous cell carcinoma |
| Therapies | |
| Age Groups: | senior adult |